Alphina Therapeutics is a biotechnology company that aims to leverage proprietary biomarkers and breakthrough insights for cancer patients.
Alphina Therapeutics has raised $40.0M in total funding. The most recent round was Series A. The last funding was announced in September 2021.
Alphina Therapeutics's investors include Connecticut Innovations, Canaan Partners, OUP (Osage University Partners), Alexandria Venture Investments, HighCape Partners.
Alphina Therapeutics is headquartered in Westport, United States.
Alphina Therapeutics is a biotechnology company that aims to leverage proprietary biomarkers and breakthrough insights for cancer patients.
Alphina Therapeutics is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Alphina Therapeutics — Funding & Investors." VCBacked, September 9, 2021, https://www.vcbacked.co/company/alphina-therapeutics. Accessed July 18, 2026.
VCBacked. (2021). Alphina Therapeutics — Funding & Investors. Retrieved July 18, 2026, from https://www.vcbacked.co/company/alphina-therapeutics
{{cite web |title=Alphina Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/alphina-therapeutics |website=VCBacked |access-date=July 18, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated